OBJECTIVE: To assess the effectiveness of generic anti-retroviral drugs in terms of survival and virological and immunological responses, as well as their tolerability and the emergence of viral resistance. METHODS: A total of 109 HIV-1-infected patients were enrolled in a prospective cohort study in Yaoundé, Cameroon. Available generic drugs were a fixed-dose combination (FDC) of zidovudine (ZDV) and lamivudine (3TC), an FDC of 3TC, stavudine (d4T) and nevirapine (NVP), and individual formulations of ZDV, 3TC and NVP. RESULTS: At baseline, the median CD4 cell count was 150/mm3 [interquartile range (IQR) 61-223] and median viral load was 5.4 log10 copies/ml (IQR 4.8-5.6); 78% of patients received ZDV/3TC/NVP and 22% received 3TC/d4T/NVP. Median follow-up was 16 months (IQR 11-23). The survival probability was high (0.92 at 12 months); plasma viral load declined by a median of 3.3 log10 copies/ml and 86.9% of the intention-to-treat population had viral load <400 copies/ml at 12 months; CD4 count had increased by a median of 106 cells/mm3 at 12 months; drug resistance rarely emerged (incidence rate 3.2 per 100 person-years); and the treatments were reasonably well-tolerated (incidence rate of severe adverse effects 7.8 per 100 person-years). CONCLUSION: Together with previous pharmacological and clinical studies, this prospective study suggests that these generic antiretroviral drugs can be used in developing countries.
OBJECTIVE: To assess the effectiveness of generic anti-retroviral drugs in terms of survival and virological and immunological responses, as well as their tolerability and the emergence of viral resistance. METHODS: A total of 109 HIV-1-infectedpatients were enrolled in a prospective cohort study in Yaoundé, Cameroon. Available generic drugs were a fixed-dose combination (FDC) of zidovudine (ZDV) and lamivudine (3TC), an FDC of 3TC, stavudine (d4T) and nevirapine (NVP), and individual formulations of ZDV, 3TC and NVP. RESULTS: At baseline, the median CD4 cell count was 150/mm3 [interquartile range (IQR) 61-223] and median viral load was 5.4 log10 copies/ml (IQR 4.8-5.6); 78% of patients received ZDV/3TC/NVP and 22% received 3TC/d4T/NVP. Median follow-up was 16 months (IQR 11-23). The survival probability was high (0.92 at 12 months); plasma viral load declined by a median of 3.3 log10 copies/ml and 86.9% of the intention-to-treat population had viral load <400 copies/ml at 12 months; CD4 count had increased by a median of 106 cells/mm3 at 12 months; drug resistance rarely emerged (incidence rate 3.2 per 100 person-years); and the treatments were reasonably well-tolerated (incidence rate of severe adverse effects 7.8 per 100 person-years). CONCLUSION: Together with previous pharmacological and clinical studies, this prospective study suggests that these generic antiretroviral drugs can be used in developing countries.
Authors: James H McMahon; Julian H Elliott; Silvia Bertagnolio; Rachel Kubiak; Michael R Jordan Journal: Bull World Health Organ Date: 2013-02-21 Impact factor: 9.408
Authors: Amanda H Corbett; Mina C Hosseinipour; Jean Nyirenda; Cecelia Kanyama; Naser L Rezk; Pax Mkupani; Dorothy Sichali; Hsiao Tien; Angela Dm Kashuba; Charles Mwansambo; Ralf Weigel; Peter Kazembe Journal: Antivir Ther Date: 2010
Authors: Jules B Tchatchueng Mbougua; Christian Laurent; Charles Kouanfack; Anke Bourgeois; Laura Ciaffi; Alexandra Calmy; Henri Gwet; Sinata Koulla-Shiro; Jacques Ducos; Eitel Mpoudi-Ngolé; Nicolas Molinari; Eric Delaporte Journal: BMC Public Health Date: 2010-03-01 Impact factor: 3.295
Authors: Mireia Arnedo; Elena Alonso; Nell Eisenberg; Laura Ibáñez; Cecilia Ferreyra; Angels Jaén; Laurence Flevaud; Samuel Khamadi; Paul Roddy; Jose Maria Gatell; David Dalmau Journal: PLoS One Date: 2012-12-06 Impact factor: 3.240
Authors: Alexandra Calmy; Eric Balestre; Fabrice Bonnet; Andrew Boulle; Eduardo Sprinz; Robin Wood; Eric Delaporte; Eugène Messou; James McIntyre; Kamal Marhoum El Filali; Mauro Schechter; N Kumarasamy; David Bangsberg; Patrick McPhail; Stefaan Van Der Borght; Carlos Zala; Matthias Egger; Rodolphe Thiébaut; François Dabis Journal: BMC Infect Dis Date: 2012-06-28 Impact factor: 3.090
Authors: Jeffrey S A Stringer; Albert J Mwango; Mark J Giganti; Lloyd Mulenga; Jens W Levy; Elizabeth M Stringer; Priscilla Mulenga; Michael S Saag; Patrick Musonda; Frank B Williams; Stewart E Reid; Benjamin H Chi Journal: Int J Epidemiol Date: 2012-04 Impact factor: 7.196
Authors: M Azabji-Kenfack; S Edie Dikosso; E G Loni; E A Onana; E Sobngwi; E Gbaguidi; A L Ngougni Kana; G Nguefack-Tsague; D Von der Weid; O Njoya; J Ngogang Journal: Nutr Metab Insights Date: 2011-05-02